Key facts
- This page summarizes ARMISTICE CAPITAL, LLC's Form 4 filing for AYTU BIOPHARMA, INC (AYTU).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 May 2021, 21:25.
ARMISTICE CAPITAL, LLC - 20 Mar 2021 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)
- Reporting relationship
- Director
- Issuer ticker
- AYTU
- Reported as of
- 20 Mar 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 May 2021, 21:25:21 UTC
- Next SEC filing
- 18 May 2021
- Source filing
- View source filing
- Reporting owner signature
- Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
ARMISTICE CAPITAL, LLC filed Form 4 for AYTU BIOPHARMA, INC (AYTU) on 10 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AYTU
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +6,959
- Change %
- +0.52%
- Price
- $0.000000
- Shares after
- 1,340,293
- Date
- 20 Mar 2021
- Ownership
- Direct
- Footnotes
- F1, F2
AYTU
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- 0
- Change %
- 0%
- Price
- $0.000000*
- Shares after
- 1,340,293
- Date
- 20 Mar 2021
- Ownership
- See Footnote 1
- Footnotes
- F2
AYTU
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +2,085
- Change %
- +0.16%
- Price
- $0.000000
- Shares after
- 1,342,378
- Date
- 29 Mar 2021
- Ownership
- Direct
- Footnotes
- F1, F2
AYTU
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- 0
- Change %
- 0%
- Price
- $0.000000*
- Shares after
- 1,342,378
- Date
- 29 Mar 2021
- Ownership
- See Footnote 1
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported shares of common stock (the "Shares") of Aytu BioPharma, Inc. (the "Issuer") are directly held by Armistice s (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
Footnote F2
The reported Shares were acquired by the Master Fund from the Issuer as a result of 300,000 non-transferable contingent value rights (collectively, the "CVRs") granted to the Master Fund as a former shareholder of Innovus Pharmaceuticals, Inc ("Innovus") upon consummation of the merger between the Issuer and Innovus on February 14, 2020. The number of Shares received by the Master Fund pursuant to the CVRs was determined by the Issuer through the application of a formula based on the Issuer's achievement of certain revenue and profitability milestones.
SEC remarks
Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd, a representative of the Master Fund and Armistice Capital, currently serves on the Issuer's board of directors.